Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Prelude Therapeutics (PRLD) Return on Capital Employed (2024 - 2026)

Prelude Therapeutics' Return on Capital Employed history spans 3 years, with the latest figure at 94.79% for Q1 2026.

  • On a quarterly basis, Return on Capital Employed rose 620.0% to 94.79% in Q1 2026 year-over-year; TTM through Mar 2026 was 94.79%, a 620.0% increase, with the full-year FY2025 number at 99.19%, down 2966.0% from a year prior.
  • Return on Capital Employed hit 94.79% in Q1 2026 for Prelude Therapeutics, up from 160.77% in the prior quarter.
  • Over the last five years, Return on Capital Employed for PRLD hit a ceiling of 86.93% in Q4 2024 and a floor of 160.77% in Q4 2025.
  • Historically, Return on Capital Employed has averaged 118.19% across 3 years, with a median of 113.48% in 2025.
  • Biggest five-year swings in Return on Capital Employed: tumbled -7384bps in 2025 and later surged 620bps in 2026.
  • Tracing PRLD's Return on Capital Employed over 3 years: stood at 86.93% in 2024, then crashed by -85bps to 160.77% in 2025, then skyrocketed by 41bps to 94.79% in 2026.
  • Business Quant data shows Return on Capital Employed for PRLD at 94.79% in Q1 2026, 160.77% in Q4 2025, and 139.7% in Q3 2025.